Evidence map›Paper›PMID 41060585›Full record

ArticleMycopathologia2025

Global, Regional, and National Disability-Adjusted Life Years Burdens of Lower Respiratory Tract Fungal Infections, 1990-2021: A Systematic Analysis of the Global Burden of Disease Study 2021.

Zhiwei Long, Longzhen Lu, Guisheng Xian, Zhengtu Li, Mingkai Guo, Aguo Li, Zhenlin Guan, Feng Ye, Yan Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Mycopathologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhiwei Long *State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Longzhen Lu *State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Guisheng Xian *Department of Clinical Medicine, Guangzhou Medical University, Guangzhou, China.
Zhengtu LiState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Mingkai GuoThe Third School of Clinical Medicine, Guangzhou Medical University, Guangzhou, China.
Aguo LiDepartment of Clinical Medicine, Guangzhou Medical University, Guangzhou, China.
Zhenlin GuanDepartment of Clinical Medicine, Guangzhou Medical University, Guangzhou, China.
Feng YeState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. tu276025@gird.cn.
Yan WangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 345406739@qq.com.

Funding

Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0506200Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0506204
6 · The paper itself

Abstract

backgroundLower respiratory tract fungal infections (LRTFIs) contribute significantly to global disease burden, yet systematic research is limited. This study analyzes their disability-adjusted life year (DALY) burden, exploring trends, geographic patterns, demographic differences, driving factors, and inequalities.

methodsUsing Global Burden of Disease Study 2021 data, we analyzed global, regional, and national DALYs trends from 1990 to 2021 and forecasted burden to 2050. Decomposition analysis evaluated impacts of population growth, ageing, and epidemiological changes. We analyzed national burden inequalities using the Slope Index of Inequality and the Concentration Index.

resultsGlobal DALYs from LRTFIs decreased slightly from 1.32 to 1.30 million (1990-2021), with an age-standardized DALY rate (ASDR) decline from 25.86 to 16.37 per 100,000 (EAPC = - 1.52). The highest ASDRs were in low-SDI regions, particularly Central Sub-Saharan Africa (71.86 per 100,000). Zimbabwe, Lesotho, and the Central African Republic had the highest national burdens. Males and individuals over 50 had higher DALY rates. Population growth increased DALYs, while ageing and epidemiological shifts reduced then. Absolute inequality declined, but relative inequality increased. By 2050, DALYs are projected to rise to 1.78 million, though ASDR will decline to 10.37 per 100,000.

conclusionsDespite progress, LRTFIs burden remains high in underdeveloped regions, particularly Africa. Population growth and ageing will drive future challenges, and significant global inequalities in disease burden persist.

Indexed as

Disability-Adjusted Life YearsGlobal Burden of DiseaseMycosesRespiratory Tract InfectionsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleGlobal HealthHumansInfantInfant, NewbornMaleDisability-adjusted life yearsEpidemiologyFungiLower respiratory infectionsMycoses

Identifiers

PMID41060585

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.